Strategic Pharma and Biotech Consultants with Diverse, Real-World Experience

Q&A on how traditional pharmaceutical distribution must be transformed to meet the challenges of revolutionary Cell and Gene Therapies.

Pharmaceutical Executive worked with Archbow’s distribution experts, Kevin Cast, Rob Besse, and Paul Furgal, to find out which trends we should be watching as we welcome 2020.

A well-organized Ad Board can provide a pharmaceutical manufacturer with numerous advantages over traditional, structured market-research. These 5 essentials will help your next Ad Board be a success.

In a Q&A, Rob Besse shares his thoughts on making the leap from his family’s business to consulting, what manufacturers need to know before commercialization planning, and industry trends worth watching.

When manufacturers are planning the launch of a Buy-and-Bill product, there are certain steps that are imperative to include in the launch strategy and development of support services.

Determining if your HUB should be insourced, outsourced, or a hybrid of those two options is a big decision. And finding the right answer can determine the future success of your patient access program.

Before establishing an Expanded Access Program, it’s vital for manufacturers to align internally around several crucial program decisions. These five are key.

With no roadmap for Cell and Gene Therapy, it can be overwhelming to try to stay on top of all the moving parts. This overview of 4 key CGT topics will keep you up to date.

In addition to saving time and money, investing in project management can provide competitive advantage. If your organization can deliver strategic projects quicker and more efficiently, and fewer projects fail, it positively impacts the bottom line. Includes 5 ways to...

Key takeaways from 2019 World Congress Integrate meeting. Six essentials for improving support and access from manufacturers to patients, providers, and networks. IDNs, SP contracts, 501c3 compliance, VBCs, and more.